Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 22 | 2023 | 331 | 6.030 |
Why?
|
| Cell Cycle Proteins | 11 | 2023 | 230 | 4.250 |
Why?
|
| Cyclin-Dependent Kinases | 13 | 2022 | 60 | 3.580 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2021 | 411 | 3.560 |
Why?
|
| Drug Design | 14 | 2023 | 107 | 2.910 |
Why?
|
| Antineoplastic Agents | 15 | 2022 | 1070 | 2.540 |
Why?
|
| Adenosine Triphosphate | 9 | 2021 | 314 | 2.410 |
Why?
|
| Peptides | 11 | 2020 | 455 | 2.210 |
Why?
|
| Structure-Activity Relationship | 25 | 2022 | 420 | 1.940 |
Why?
|
| Peptidomimetics | 3 | 2020 | 7 | 1.720 |
Why?
|
| Cyclin-Dependent Kinase 2 | 11 | 2016 | 33 | 1.590 |
Why?
|
| Models, Molecular | 26 | 2022 | 546 | 1.370 |
Why?
|
| Cyclins | 5 | 2014 | 50 | 1.130 |
Why?
|
| Molecular Structure | 16 | 2022 | 397 | 1.120 |
Why?
|
| Protein Binding | 17 | 2020 | 1027 | 1.030 |
Why?
|
| Neoplasms | 5 | 2023 | 1664 | 0.940 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2022 | 15 | 0.810 |
Why?
|
| Molecular Docking Simulation | 5 | 2022 | 78 | 0.760 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 194 | 0.710 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 299 | 0.670 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 25 | 0.670 |
Why?
|
| Enzyme Inhibitors | 7 | 2011 | 659 | 0.650 |
Why?
|
| Protein Structure, Tertiary | 9 | 2021 | 322 | 0.650 |
Why?
|
| Ligands | 9 | 2021 | 317 | 0.600 |
Why?
|
| Benzamides | 2 | 2016 | 156 | 0.560 |
Why?
|
| Computer Simulation | 4 | 2010 | 706 | 0.480 |
Why?
|
| Humans | 38 | 2023 | 68549 | 0.450 |
Why?
|
| Benzothiazoles | 2 | 2018 | 14 | 0.450 |
Why?
|
| Arginine | 1 | 2013 | 102 | 0.440 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2010 | 38 | 0.440 |
Why?
|
| Crystallography, X-Ray | 14 | 2010 | 190 | 0.440 |
Why?
|
| Binding Sites | 12 | 2018 | 631 | 0.430 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 57 | 0.420 |
Why?
|
| Oligopeptides | 1 | 2013 | 152 | 0.410 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2010 | 137 | 0.410 |
Why?
|
| Cell Line, Tumor | 9 | 2022 | 1851 | 0.410 |
Why?
|
| Protein Conformation | 10 | 2013 | 362 | 0.390 |
Why?
|
| Pyrimidines | 6 | 2010 | 178 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 1745 | 0.390 |
Why?
|
| Cyclin D1 | 1 | 2010 | 37 | 0.370 |
Why?
|
| HeLa Cells | 4 | 2021 | 237 | 0.370 |
Why?
|
| Drug Discovery | 3 | 2018 | 94 | 0.340 |
Why?
|
| Phenotype | 1 | 2012 | 946 | 0.340 |
Why?
|
| Protein Kinases | 2 | 2006 | 122 | 0.330 |
Why?
|
| Cell Proliferation | 6 | 2021 | 1174 | 0.330 |
Why?
|
| Cyclin A | 5 | 2015 | 11 | 0.320 |
Why?
|
| Binding, Competitive | 5 | 2015 | 165 | 0.320 |
Why?
|
| Small Molecule Libraries | 2 | 2021 | 53 | 0.320 |
Why?
|
| Animals | 18 | 2022 | 20880 | 0.310 |
Why?
|
| Substrate Specificity | 3 | 2022 | 234 | 0.310 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 111 | 0.310 |
Why?
|
| Cyclic N-Oxides | 1 | 2006 | 17 | 0.290 |
Why?
|
| Spindle Apparatus | 1 | 2006 | 13 | 0.290 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 80 | 0.270 |
Why?
|
| Cell Cycle | 4 | 2014 | 312 | 0.260 |
Why?
|
| Drug Industry | 1 | 2005 | 54 | 0.250 |
Why?
|
| Thiazoles | 3 | 2010 | 95 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 216 | 0.230 |
Why?
|
| Leukemia | 2 | 2022 | 117 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2022 | 304 | 0.210 |
Why?
|
| Iron Chelating Agents | 1 | 2022 | 31 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 2 | 2022 | 532 | 0.200 |
Why?
|
| Biological Availability | 1 | 2022 | 79 | 0.200 |
Why?
|
| Quinolines | 1 | 2022 | 48 | 0.200 |
Why?
|
| Benzoic Acid | 1 | 2021 | 5 | 0.200 |
Why?
|
| Cell Survival | 3 | 2021 | 901 | 0.200 |
Why?
|
| Cell Line | 3 | 2019 | 1752 | 0.190 |
Why?
|
| Fluorescent Dyes | 1 | 2022 | 191 | 0.190 |
Why?
|
| Dimerization | 2 | 2019 | 99 | 0.190 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2019 | 107 | 0.180 |
Why?
|
| Protein Domains | 1 | 2020 | 74 | 0.180 |
Why?
|
| Phosphorylation | 3 | 2015 | 1200 | 0.170 |
Why?
|
| Mice | 8 | 2022 | 8474 | 0.170 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2019 | 34 | 0.170 |
Why?
|
| Mitochondria | 2 | 2022 | 643 | 0.170 |
Why?
|
| Pyrroles | 2 | 2013 | 83 | 0.160 |
Why?
|
| Pteridines | 1 | 2018 | 5 | 0.160 |
Why?
|
| Apoptosis | 3 | 2015 | 1641 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 175 | 0.160 |
Why?
|
| Catalytic Domain | 1 | 2018 | 99 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 247 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2006 | 97 | 0.150 |
Why?
|
| Acetylcholinesterase | 1 | 2016 | 19 | 0.140 |
Why?
|
| Ranitidine | 1 | 2016 | 16 | 0.140 |
Why?
|
| Computational Biology | 3 | 2007 | 190 | 0.140 |
Why?
|
| Nootropic Agents | 1 | 2016 | 18 | 0.140 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2016 | 58 | 0.140 |
Why?
|
| CDC2-CDC28 Kinases | 3 | 2005 | 17 | 0.140 |
Why?
|
| Quantitative Structure-Activity Relationship | 2 | 2006 | 16 | 0.130 |
Why?
|
| Cyclin A2 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2006 | 35 | 0.130 |
Why?
|
| Mitosis | 2 | 2012 | 76 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 700 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 19 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 376 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 65 | 0.110 |
Why?
|
| Triazoles | 1 | 2013 | 43 | 0.110 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2013 | 85 | 0.110 |
Why?
|
| cdc25 Phosphatases | 1 | 2012 | 2 | 0.110 |
Why?
|
| Dipeptides | 1 | 2013 | 89 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2012 | 42 | 0.110 |
Why?
|
| Estradiol | 1 | 2013 | 176 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2010 | 346 | 0.100 |
Why?
|
| Estrogens | 1 | 2013 | 173 | 0.100 |
Why?
|
| Amino Acid Sequence | 4 | 2009 | 1082 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2013 | 190 | 0.100 |
Why?
|
| Protein Transport | 1 | 2012 | 280 | 0.100 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Calpain | 1 | 2012 | 205 | 0.100 |
Why?
|
| Structural Homology, Protein | 1 | 2010 | 16 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2010 | 14 | 0.090 |
Why?
|
| Peptide Library | 2 | 2006 | 16 | 0.090 |
Why?
|
| Protein Structure, Secondary | 3 | 2005 | 136 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 236 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 76 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2009 | 87 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2009 | 220 | 0.080 |
Why?
|
| Centrosome | 1 | 2006 | 6 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2012 | 73 | 0.070 |
Why?
|
| Protein Engineering | 1 | 2006 | 35 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2006 | 169 | 0.070 |
Why?
|
| Microtubules | 1 | 2006 | 104 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 1446 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 58 | 0.060 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2005 | 22 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 1 | 2005 | 8 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 13 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 26 | 0.060 |
Why?
|
| Protein Structure, Quaternary | 1 | 2005 | 31 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 50 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 93 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 35 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2004 | 5 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 134 | 0.060 |
Why?
|
| Hydrogen Bonding | 3 | 2013 | 66 | 0.060 |
Why?
|
| Software | 2 | 2006 | 418 | 0.060 |
Why?
|
| Calcium | 2 | 2022 | 929 | 0.060 |
Why?
|
| Aniline Compounds | 1 | 2004 | 52 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 271 | 0.060 |
Why?
|
| Piperazines | 1 | 2005 | 206 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2005 | 239 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1293 | 0.060 |
Why?
|
| Oxyquinoline | 1 | 2022 | 6 | 0.050 |
Why?
|
| Rhodamine 123 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Thapsigargin | 1 | 2022 | 18 | 0.050 |
Why?
|
| Cations, Divalent | 1 | 2022 | 27 | 0.050 |
Why?
|
| Fluorescence | 1 | 2022 | 104 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 113 | 0.050 |
Why?
|
| Algorithms | 1 | 2007 | 1195 | 0.050 |
Why?
|
| Time Factors | 1 | 2006 | 4655 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2009 | 137 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2022 | 2673 | 0.040 |
Why?
|
| Receptor, Muscarinic M4 | 1 | 2016 | 2 | 0.040 |
Why?
|
| Naphthalimides | 1 | 2016 | 5 | 0.040 |
Why?
|
| Butyrylcholinesterase | 1 | 2016 | 9 | 0.040 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2016 | 17 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 231 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 134 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 81 | 0.030 |
Why?
|
| Databases, Protein | 2 | 2005 | 49 | 0.030 |
Why?
|
| Macromolecular Substances | 2 | 2005 | 122 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2015 | 368 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Biochemistry | 1 | 2012 | 12 | 0.030 |
Why?
|
| Oleic Acid | 1 | 2012 | 40 | 0.030 |
Why?
|
| Cytosol | 1 | 2012 | 123 | 0.030 |
Why?
|
| Cysteine | 1 | 2012 | 112 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 565 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2010 | 2 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 3 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2009 | 35 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2009 | 28 | 0.020 |
Why?
|
| Rad51 Recombinase | 1 | 2009 | 16 | 0.020 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2009 | 25 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2009 | 43 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2009 | 62 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2009 | 89 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 188 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 160 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 562 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 246 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 235 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 954 | 0.020 |
Why?
|
| Kidney | 1 | 2012 | 945 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1047 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2005 | 24 | 0.020 |
Why?
|
| Xenopus | 1 | 2005 | 30 | 0.020 |
Why?
|
| Protein Folding | 1 | 2005 | 82 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2005 | 165 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 5300 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2009 | 902 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2003 | 77 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2550 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 261 | 0.010 |
Why?
|
| Female | 1 | 2009 | 38021 | 0.000 |
Why?
|